IHC of BRAF V600E on an FFPE Papillary Thyroid Carcinoma Tissue

United States
International
Research Use
Safety Data Sheet

SDS

Control Slides
Intended Use For Analyte Specific Reagent
Summary and Explanation

BRAF is a human gene that makes a protein called B-Raf, which is more formally known as serine/threonine-protein kinase B-Raf.  The B-Raf protein is involved in sending signals inside cells, which are involved in directing cell growth. In 2002, it was shown to be mutated in some human cancers.  Mutations in the BRAF gene can cause disease in two ways. First, mutations can be inherited and cause birth defects. Second, mutations can appear later in life and cause cancer, as an oncogene.

Mutations in this gene have been found in cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, papillary thyroid carcinoma, non-small-cell lung carcinoma, and adenocarcinoma of the lung. The frequency of BRAF mutations varies widely in human cancers, from more than 80% in melanomas and nevi, to as little as 0–18% in other tumors, such as 1–3% in lung cancers and 5% in colorectal cancer. In 90% of the cases, thymine is substituted with adenine at nucleotide 1799. This leads to valine (V) being substituted for by glutamate (E) at codon 600 (referred to as V600E) in the activation segment that has been found in human cancers. This mutation has been widely observed in papillary thyroid carcinoma, colorectal cancer, melanoma and non-small-cell lung cancer. BRAF-V600E mutation are present in 57% of Langerhans cell histiocytosis patients. The V600E mutation is a likely driver mutation in 100% of cases of hairy cell leukemia. High frequency of BRAF V600E mutations have been detected in ameloblastoma, a benign but locally infiltrative odontogenic neoplasm.

Antibody Type Rabbit Monoclonal Clone RM8
Isotype IgG Reactivity Paraffin, Frozen
Localization Cytoplasmic Control BRAF 600E Mutated Melanoma, Papillary Thyroid Cancer
Presentation BRAF V600E is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Availability
Catalog No. Antibody Type Dilution Volume/QTY
BSB 2824 Prediluted Ready-To-Use 3.0 ml
BSB 2825 Prediluted Ready-To-Use 7.0 ml
BSB 2826 Prediluted Ready-To-Use 15.0 ml
BSB 2827 Concentrated 1:50-1:200 0.1 ml
BSB 2828 Concentrated 1:50-1:200 0.5 ml
BSB 2829 Concentrated 1:50-1:200 1.0 ml
BSB 2830 Control Slides 5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.
Related Products